Research on Primary Immunodeficiency Disease Market
Abnormal functioning of immune system due to lack of necessary antibodies or lack of normal functioning of present antibodies is referred as primary immunodeficiency disease. Immunodeficiency is referred as primary immunodeficiency when any disease, environmental exposure to toxins or drug treatment is not the cause of the disease. Primary immunodeficiency disease is also referred as primary immune disorder or primary immunodeficiency disorder. Approximately one in every 500 people is observed to have primary immunodeficiency disease.
Primary immunodeficiency disease is a genetic disorder. Signs and symptoms of primary immunodeficiency disorder include recurrent bronchitis, pneumonia, meningitis, and ear infection. In addition, sinus infection, blood infection, skin infection, infection of internal organs, inflammation, and delayed development and growth are also observed. In addition, loss of appetite, diarrhea, nausea, cramping, digestive problems, blood disorders including, anemia, and low platelet count are also observed in some cases. Immunodeficiency disorder is commonly diagnosed in infants. However, mild form of primary immunodeficiency may not be diagnosed until adulthood. Based on the types, the global primary immunodeficiency disorder market is segmented as follows:
- B cell (antibody) deficiencies
- T cell deficiencies
- Combination B and T cell deficiencies
- Defective phagocytes
- Combination B and T cell deficiencies
- Complement deficiencies
- Unknown (idiopathic)
Based on the diagnostic tests, global primary immunodeficiency disorder market is segmented as follows:
- Blood Tests
- Prenatal Testing
- DNA Testing
- Tissue and Placental Sample Testing
Based on the treatment, global primary immunodeficiency disorder market is segmented as follows:
Antibiotics for Treating Symptoms
Treatment to Boost the Immune System
- Immunoglobulin Therapy
- Gamma Interferon Therapy
- Growth Factors
Treatment to Cure Primary Immunodeficiency
Stem Cell Transplantation
Geographically, the global primary immunodeficiency disorder market is segmented as North America, Europe, Asia-Pacific, and Rest of the World (RoW) regions. Presently, North America is dominating the global primary immunodeficiency disorders market. Europe is the second largest market in the overall primary immunodeficiency disease market. Exceptionally developed healthcare infrastructure, reimbursement coverage, higher healthcare spending, availability of advanced healthcare technology, and high rate of awareness about primary immunodeficiency disease are few of the major factors that are driving the growth of the primary immunodeficiency disease market in North America and Europe. Asia-Pacific is a lucrative market for primary immunodeficiency diseases market.
Rapidly developing healthcare infrastructure, increasing disposable income and government initiatives to improve healthcare industry in respective country on the ground of rapidly growing medical tourism industry are some of the factors that are driving the growth of primary immunodeficiency disease market in Asia-Pacific. China and India are expected to grow swiftly owing to rapidly developing medical tourism industry in these countries. Apart from China and India, Japan is expected to contribute in the growth of the primary immunodeficiency disease market in Asia due to increased focus of Japanese government to offer improved and advanced healthcare facilities to Japanese citizens. Mexico, Brazil, and Argentina are the countries in the Rest of the World (RoW) region that are expected to demonstrate faster growth in the primary immunodeficiency market than African countries. Middle Eastern countries along with rest of the Latin American countries are expected to be second fastest growing markets for the primary immunodeficiency disease in the Rest of the World (RoW) region.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.